Provectus Biopharmaceuticals, Inc. — Cyborg Score 3/10
Challenged
Clinical-stage immunotherapy and photodynamic therapy
Strategic Profile
Provectus Biopharmaceuticals remains a clinical-stage company with no product revenue. The company reported a net loss of $1.3 million for the three months ended March 31, 2026, compared with $1.16 million a year earlier. The company is relocating from its current offices at 800 S. Gay Street to Perkins Place, which is its planned new headquarters in 2026.
Cyborg Score Rationale
The company discloses that substantial doubt exists about its ability to continue as a going concern and must secure additional financing, including through convertible notes, equity offerings, or collaborations to fund operations and planned clinical development. Early-stage drug development with no product revenue and limited cash ($223,883 at Q1 2026) creates significant execution and funding risk.
Top Insights
Clinical-stage company with no approved products or product revenue; entirely dependent on grant funding and equity raises
Rose Bengal Sodium platform being developed across multiple therapeutic areas (oncology, dermatology, ophthalmology) to diversify risk
Critical liquidity crisis: $224K cash at Q1 2026 against $6.78M working capital deficit and $264.1M accumulated deficit
Recent developments include preclinical bladder cancer data (May 2026) and Rose Bengal photodynamic antimicrobial therapy presentations (May 2026)
Named Competitors
Yervoy — Immunotherapy for oncology indications
Opdivo — Checkpoint inhibitor immunotherapy
Keytruda — PD-1 inhibitor for oncology
Recent Developments
(May 2026) Bascom Palmer Eye Institute presented four posters on Rose Bengal photodynamic antimicrobial therapy at ARVO 2026
(May 2026) Reported oral PV-10 anti-tumor activity in preclinical bladder cancer study with long-term survivors showing absence of gross bladder tumor
(June 2026) Held annual stockholder meeting at Perkins Place in Knoxville, the planned new headquarters location
Open the full interactive Provectus Biopharmaceuticals, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.